Jinyang Hu

发表

Glioblastoma Immunotherapy Targeting the Innate Immune Checkpoint CD47-SIRPα Axis

Xudong Wu, Bao-feng Wang, D. Guo, 2020, Frontiers in Immunology.

Targeting LRIG2 overcomes resistance to EGFR inhibitor in glioblastoma by modulating GAS6/AXL/SRC signaling

Yue He, T. Lei, Bao-feng Wang, 2020, Cancer Gene Therapy.

JUN activation modulates chromatin accessibility to drive TNFα‐induced mesenchymal transition in glioblastoma

Xudong Wu, Yingying Zhao, Qian Li, 2022, Journal of cellular and molecular medicine.

LRIG2 promotes glioblastoma progression by modulating innate antitumor immunity through macrophage infiltration and polarization

Xudong Wu, Bao-feng Wang, D. Guo, 2022, Journal for ImmunoTherapy of Cancer.

Targeting LRIG2 overcomes resistance to EGFR inhibitor in glioblastoma by modulating GAS6/AXL/SRC signaling

Yue He, T. Lei, Bao-feng Wang, 2020, Cancer Gene Therapy.

ALKBH5 Facilitates Hypoxia-Induced Paraspeckle Assembly and IL8 Secretion to Generate an Immunosuppressive Tumor Microenvironment

Xudong Wu, Xuan Cheng, C. Kang, 2021, Cancer Research.

Tenascin-C can Serve as an Indicator for the Immunosuppressive Microenvironment of Diffuse Low-Grade Gliomas

Peng Peng, Bao-feng Wang, Sui Chen, 2022, Frontiers in Immunology.

Natural and synthetic compounds for glioma treatment based on ROS-mediated strategy.

Yufei Wang, Jinyang Hu, 2023, European journal of pharmacology.

mTORC2 regulates hierarchical micro/nano topography‐induced osteogenic differentiation via promoting cell adhesion and cytoskeletal polymerization

Dawei Huo, Xudong Wu, Lei Sui, 2021, Journal of cellular and molecular medicine.